727357-57-5

Usage

Uses

Used in Pharmaceutical Industry:
2-oxo-2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetic acid is utilized as a potential therapeutic agent for the treatment of various diseases, primarily due to its structural attributes and the possibility of modulating biological pathways relevant to these conditions.
Used in Oncology:
In the field of oncology, 2-oxo-2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetic acid is considered for its potential role in cancer treatment. Its heterocyclic nature suggests that it may interact with cellular targets, thereby affecting cancer cell proliferation, survival, or other processes that contribute to tumorigenesis.
Used in Neurological Disorders:
For neurological disorders, 2-oxo-2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetic acid is hypothesized to have applications due to its structural relationship with tryptophan, an amino acid that is a precursor to serotonin, a neurotransmitter with implications in mood regulation and other neurological functions. This relationship may provide a basis for its use in the development of treatments for conditions such as depression, anxiety, and other mood-related disorders.

Downstream Products

• 357262-85-2 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[3,2-b]-pyridin-3-yl)ethane-1,2-dione 

Relevant academic research and scientific papers

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]-pyridin-3-yl) ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects

Azaindole derivatives derived from the screening lead 1-(4- benzoylpiperazin-1-yl)-2-(1H-indol-3-yl)ethane-1,2-dione (1) were prepared and characterized to assess their potential as inhibitors of HIV-1 attachment. Systematic replacement of each of the unfused carbon atoms in the phenyl ring of the indole moiety by a nitrogen atom provided four different azaindole derivatives that displayed a clear SAR for antiviral activity and all of which displayed marked improvements in pharmaceutical properties. Optimization of these azaindole leads resulted in the identification of two compounds that were advanced to clinical studies: (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(4- methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione (BMS-377806, 3) and 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl) ethane-1,2-dione (BMS-488043, 4). In a preliminary clinical study, 4 administered as monotherapy for 8 days, reduced viremia in HIV-1-infected subjects, providing proof of concept for this mechanistic class.